Resveratrol attenuates hyperglycemia-mediated oxidative stress, proinflammatory cytokines and protects hepatocytes ultrastructure in streptozotocin-nicotinamide-induced experimental diabetic rats

Chemico-Biological Interactions

Volumn 186, Issue 2, 2010, Pages 200-210

  Palsamy, P ^a   Sivakumar, S ^a   Subramanian, S ^a  

^a UNIVERSITY OF MADRAS   (India)

Author keywords

Diabetic liver; Lipid peroxidation; Oxidative stress; Proinflammatory cytokines; Resveratrol

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALPHA TOCOPHEROL; ASCORBIC ACID; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARBONYL DERIVATIVE; CATALASE; CYTOKINE; GLICLAZIDE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPID HYDROPEROXIDE; LIPID PEROXIDE; NICOTINAMIDE; NITRIC OXIDE; RESVERATROL; STREPTOZOCIN; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CELL FUNCTION; CELL ULTRASTRUCTURE; CONTROLLED STUDY; CYTOKINE RELEASE; DIABETES MELLITUS; ENZYME ACTIVITY; HISTOPATHOLOGY; HYPERGLYCEMIA; LIPID PEROXIDATION; LIVER PARENCHYMA; LIVER PROTECTION; MALE; NONHUMAN; OXIDATIVE STRESS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RAT; STREPTOZOCIN DIABETES;

ANIMALS; ANTIOXIDANTS; CYTOKINES; DIABETES MELLITUS, EXPERIMENTAL; GLICLAZIDE; HEPATOCYTES; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INFLAMMATION MEDIATORS; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; MODELS, BIOLOGICAL; NIACINAMIDE; OXIDATIVE STRESS; RATS; RATS, WISTAR; STILBENES;

RATTUS;

EID: 77953545677     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2010.03.028     Document Type: Article

References (76)

1. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2010, 33(Suppl. 1):S62-S69.
2. Poitout V., Robertson R.P. Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr. Rev. 2008, 29:351-366.
3. Brownlee M. A radical explanation for glucose-induced beta cell dysfunction. J. Clin. Invest. 2003, 112:1788-1790.
4. Ling P.R., Mueller C., Smith R.J., Bistrian B.R. Hyperglycemia induced by glucose infusion causes hepatic oxidative stress and systemic inflammation, but not STAT3 or MAP kinase activation in liver in rats. Metabolism 2003, 52:868-874.
5. Shao J., Qiao L., Janssen R.C., Pagliassotti M., Friedman J.E. Chronic hyperglycemia enhances PEPCK gene expression and hepatocellular glucose production via elevated liver activating protein/liver inhibitory protein ratio. Diabetes 2005, 54:976-984.
6. Stadler K., Jenei V., von Bölcsházy G., Somogyi A., Jakus J. Increased nitric oxide levels as an early sign of premature aging in diabetes. Free Radic. Biol. Med. 2003, 35:1240-1251.
7. Kume E., Fujimura H., Matsuki N., Ito M., Aruga C., Toriumi W., Kitamura K., Doi K. Hepatic changes in the acute phase of streptozotocin (SZ)-induced diabetes in mice. Exp. Toxicol. Pathol. 2004, 55:467-480.
8. Baydas G., Canatan H., Turkoglu A. Comparative analysis of the protective effects of melatonin and vitamin E on streptozocin-induced diabetes mellitus. J. Pineal Res. 2002, 32:225-230.
9. Cho S.Y., Park J.Y., Park E.M., Choi M.S., Lee M.K., Jeon S.M., Jang M.K., Kim M.J., Park Y.B. Alternation of hepatic antioxidant enzyme activities and lipid profile in streptozotocin-induced diabetic rats by supplementation of dandelion water extract. Clin. Chim. Acta 2002, 317:109-117.
10. Hünkar T., Aktan F., Ceylan A., Karasu C. Effects of cod liver oil on tissue antioxidant pathways in normal and streptozotocin-diabetic rats. Cell Biochem. Funct. 2002, 20:297-302. Antioxidants in Diabetes-Induced Complications (ADIC) Study Group.
11. Aggarwal B.B., Bhardwaj A., Aggarwal R.S., Seeram N.P., Shishodia S., Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 2004, 24:2783-2840.
12. Brisdelli F., D'Andrea G., Bozzi A. Resveratrol: a natural polyphenol with multiple chemopreventive properties. Curr. Drug Metab. 2009, 10:530-546.
13. Kopp P. Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the 'French paradox'?. Eur. J. Endocrinol. 1998, 138:619-620.
14. Das D.K., Maulik N. Resveratrol in cardioprotection: a therapeutic promise of alternative medicine. Mol. Interv. 2006, 6:36-47.
15. Zhang Y., Liu Y., Wang T., Li B., Li H., Wang Z., Yang B. Resveratrol, a natural ingredient of grape skin: antiarrhythmic efficacy and ionic mechanisms. Biochem. Biophys. Res. Commun. 2006, 340:1192-1199.
16. Leonard S.S., Xia C., Jiang B.H., Stinefelt B., Klandorf H., Harris G.K., Shi X. Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses. Biochem. Biophys. Res. Commun. 2003, 309:1017-1026.
17. Soylemez S., Gurdal H., Sepici A., Akar F. The effect of long-term resveratrol treatment on relaxation to estrogen in aortae from male and female rats: role of nitric oxide and superoxide. Vasc. Pharmacol. 2008, 49:97-105.
18. Rivera L., Morón R., Zarzuelo A., Galisteo M. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem. Pharmacol. 2009, 77:1053-1063.
19. Chen W.P., Chi T.C., Chuang L.M., Su M.J. Resveratrol enhances insulin secretion by blocking K(ATP) and K(V) channels of beta cells. Eur. J. Pharmacol. 2007, 568:269-277.
20. Szkudelski T. Resveratrol inhibits insulin secretion from rat pancreatic islets. Eur. J. Pharmacol. 2006, 552:176-181.
21. Szkudelski T. Resveratrol-induced inhibition of insulin secretion from rat pancreatic islets: evidence for pivotal role of metabolic disturbances. Am. J. Physiol. Endocrinol. Metab. 2007, 293:E901-E907.
22. Su H.C., Hung L.M., Chen J.K. Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocin-induced diabetic rats. Am. J. Physiol. Endocrinol. Metab. 2006, 290:E1339-E1346.
23. Palsamy P., Subramanian S. Resveratrol, a natural phytoalexin, normalizes hyperglycemia in streptozotocin-nicotinamide induced experimental diabetic rats. Biomed. Pharmacother. 2008, 62:598-605.
24. Palsamy P., Subramanian S. Modulatory effects of resveratrol on attenuating the key enzymes activities of carbohydrate metabolism in streptozotocin-nicotinamide-induced diabetic rats. Chem. Biol. Interact. 2009, 179:356-362.
25. Rakieten N., Rakieten M.L., Nadkarni M.R. Studies on the diabetogenic action of streptozotocin (NSC-37917). Cancer Chemother. Rep. 1963, 29:91-98.
26. Masiello P., Broca C., Gross R., Roye M., Manteghetti M., Hillaire-Buys D., Novelli M., Ribes G. Experimental NIDDM: development of a new model in adult rats administered streptozotocin and nicotinamide. Diabetes 1998, 47:224-229.
27. Fischer L.J., Rickert D.E. Pancreatic islet-cell toxicity. CRC Crit. Rev. Toxicol. 1975, 3:231-263.
28. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
29. King J. The transaminases: alanine and aspartate transaminases. Practical Clinical Enzymology 1965, Van Nostrand Reinhold Co., London, pp. 363-395.
30. King J. The hydorlases-acid and alkaline phosphatases. Practical Clinical Enzymology 1965, Van Nostrand Reinhold Co., London, pp. 199-208.
31. Malloy H.T., Evelyn K.A. The determination of bilirubin with the photoelectric colorimeter. J. Biol. Chem. 1937, 119:481-490.
32. 15N]nitrate in biological fluids. Anal. Biochem. 1982, 126:131-138.
33. Omaye S.T., Turnbull J.D., Sauberlich H.E. Selected methods for the determination of ascorbic acid in animal cells, tissues, and fluids. Methods Enzymol. 1979, 62:3-11.
34. Desai I.D. Vitamin E analysis methods for animal tissues. Methods Enzymol. 1984, 105:138-147.
35. Sedlak J., Lindsay R.H. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal. Biochem. 1968, 25:192-205.
36. Ohkawa H., Ohishi N., Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 1979, 95:351-358.
37. Jiang Z.Y., Hunt J.V., Wolff S.P. Ferrous ion oxidation in the presence of xylenol orange for detection of lipid hydroperoxide in low density lipoprotein. Anal. Biochem. 1992, 202:384-389.
38. Uchida K., Stadtman E.R. Covalent attachment of 4-hydroxynonenal to glyceraldehyde-3-phosphate dehydrogenase. A possible involvement of intra- and intermolecular cross-linking reaction. J. Biol. Chem. 1993, 268:6388-6393.
39. Misra H.P., Fridovich I. The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J. Biol. Chem. 1972, 247:3170-3175.
40. Takahara S., Hamilton H.B., Neel J.V., Kobara T.Y., Ogura Y., Nishimura E.T. Hypocatalasemia: a new genetic carrier state. J. Clin. Invest. 1960, 39:610-619.
41. Rotruck J.T., Pope A.L., Ganther H.E., Swanson A.B., Hafeman D.G., Hoekstra W.G. Selenium: biochemical role as a component of glutathione peroxidase. Science 1973, 179:588-590.
42. Habig W.H., Pabst M.J., Jakoby W.B. Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J. Biol. Chem. 1974, 249:7130-7139.
43. Carlberg I., Mannervik B. Glutathione reductase. Methods Enzymol. 1985, 113:484-490.
44. Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W., Ferrell L.D., Liu Y.C., Torbenson M.S., Unalp-Arida A., Yeh M., McCullough A.J., Sanyal A.J. Nonalcoholic steatohepatitis clinical research network, design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321.
45. Mori M. Electron microscopic and new microscopic studies of hepatocyte cytoskeleton: physiological and pathological relevance. J. Electron Microsc. (Tokyo) 1994, 43:347-355.
46. Thulesen J., Orskov C., Holst J.J., Poulsen S.S. Short-term insulin treatment prevents the diabetogenic action of streptozotocin in rats. Endocrinology 1997, 138:62-68.
47. Turk J., Corbett J.A., Ramanadham S., Bohrer A., McDaniel M.L. Biochemical evidence for nitric oxide formation from streptozotocin in isolated pancreatic islets. Biochem. Biophys. Res. Commun. 1993, 197:1458-1464.
48. Tiedge M., Lortz S., Drinkgern J., Lenzen S. Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells. Diabetes 1997, 46:1733-1742.
49. Kaneto H., Xu G., Song K.H., Suzuma K., Bonner-Weir S., Sharma A., Weir G.C. Activation of the hexosamine pathway leads to deterioration of pancreatic beta-cell function through the induction of oxidative stress. J. Biol. Chem. 2001, 276:31099-31104.
50. Michael M.D., Kulkarni R.N., Postic C., Previs S.F., Shulman G.I., Magnuson M.A., Kahn C.R. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol. Cell 2000, 6:87-97.
51. O'Brien R.M., Granner D.K. Regulation of gene expression by insulin. Biochem. J. 1991, 278:609-619.
52. Evans J.L., Goldfine I.D., Maddux B.A., Grodsky G.M. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr. Rev. 2002, 23:599-622.
53. Zhang X., Li Z., Liu D., Xu X., Shen W., Mei Z. Effects of probucol on hepatic tumor necrosis factor-alpha, interleukin-6 and adiponectin receptor-2 expression in diabetic rats. J. Gastroenterol. Hepatol. 2009, 24:1058-1063.
54. Mueller C., Imboden M.A., Hess M.W., Laissue J.A., Carnaud C.C. TNF-alpha and insulin-dependent diabetes mellitus. Res. Immunol. 1993, 144:331-335.
55. Simpson K.J., Lukacs N.W., Colletti L., Strieter R.M., Kunkel S.L. Cytokines and the liver. J. Hepatol. 1997, 27:1120-1132.
56. Cai D., Yuan M., Frantz D.F., Melendez P.A., Hansen L., Lee J., Shoelson S.E. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat. Med. 2005, 11:183-190.
57. Muriel P. NF-kappaB in liver diseases: a target for drug therapy. J. Appl. Toxicol. 2009, 29:91-100.
58. Szabo C. Role of nitrosative stress in the pathogenesis of diabetic vascular dysfunction. Br. J. Pharmacol. 2009, 156:713-727.
59. Ara C., Kirimlioglu H., Karabulut A.B., Coban S., Ay S., Harputluoglu M., Kirimlioglu V., Yilmaz S. Protective effect of resveratrol against oxidative stress in cholestasis. J. Surg. Res. 2005, 127:112-117.
60. 4 treatment in rats. J. Appl. Toxicol. 2008, 28:35-43.
61. Wu C.T., Yu H.P., Chung C.Y., Lau Y.T., Liao S.K. Attenuation of lung inflammation and pro-inflammatory cytokine production by resveratrol following trauma-hemorrhage. Chin. J. Physiol. 2008, 51:363-368.
62. Yu H., Pan C., Zhao S., Wang Z., Zhang H., Wu W. Resveratrol inhibits tumor necrosis factor-alpha-mediated matrix metalloproteinase-9 expression and invasion of human hepatocellular carcinoma cells. Biomed. Pharmacother. 2008, 62:366-372.
63. Kawada N., Seki S., Inoue M., Kuroki T. Effect of antioxidants, resveratrol, quercetin, and N-acetylcysteine, on the functions of cultured rat hepatic stellate cells and Kupffer cells. Hepatology 1998, 27:1265-1274.
64. Albano E Oxidative mechanisms in the pathogenesis of alcoholic liver disease. Mol. Aspects Med. 2008, 29:9-16.
65. Youssef W., McCullough A.J. Diabetes mellitus, obesity, and hepatic steatosis. Semin. Gastrointest. Dis. 2002, 13:17-30.
66. Jang D.S., Kang B.S., Ryu S.Y., Chang I.M., Min K.R., Kim Y. Inhibitory effects of resveratrol analogs on unopsonized zymosan-induced oxygen radical production. Biochem. Pharmacol. 1999, 57:705-712.
67. Chanvitayapongs S., Draczynska-Lusiak B., Sun A.Y. Amelioration of oxidative stress by antioxidants and resveratrol in PC12 cells. Neuroreport 1997, 8:1499-1502.
68. Sun A.Y., Chen Y.M., James-Kracke M., Wixom P., Cheng Y. Ethanol-induced cell death by lipid peroxidation in PC12 cells. Neurochem. Res. 1997, 22:1187-1192.
69. Maritim A.C., Sanders R.A., Watkins J.B. Diabetes, oxidative stress, and antioxidants: a review. J. Biochem. Mol. Toxicol. 2003, 17:24-38.
70. Rahimi R., Nikfar S., Larijani B., Abdollahi M. A review on the role of antioxidants in the management of diabetes and its complications. Biomed. Pharmacother. 2005, 59:365-373.
71. Liu Z., Li J., Zeng Z., Liu M., Wang M. The antidiabetic effects of cysteinyl metformin, a newly synthesized agent, in alloxan- and streptozocin-induced diabetic rats. Chem. Biol. Interact. 2008, 173:68-75.
72. Sanders R.A., Rauscher F.M., Watkins J.B. Effects of quercetin on antioxidant defense in streptozotocin-induced diabetic rats. J. Biochem. Mol. Toxicol. 2001, 15:143-149.
73. Opara E.C. Oxidative stress, micronutrients, diabetes mellitus and its complications. J. R. Soc. Promot. Health 2002, 122:28-34.
74. Hasanain B., Mooradian A.D. Antioxidant vitamins and their influence in diabetes mellitus. Curr. Diab. Rep. 2002, 2:448-456.
75. Balázs M., Halmos T. Electron microscopic study of liver fibrosis associated with diabetes mellitus. Exp. Pathol. 1985, 27:153-162.
76. Nepomnyashchikh G.I., Pavlenko O.A., Aidagulova S.V., Nepomnyashchikh D.L. Ultrastructural analysis of liver biopsy specimens in diabetes mellitus associated with chronic opisthorchiasis. Bull. Exp. Biol. Med. 2001, 132:1190-1194.